Medical Developments International shares on watch following Penthrox update

The Medical Developments International Ltd (ASX:MVP) share price will be on watch today after the release of a Penthrox update…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price will be on watch this morning follow a positive announcement relating to its Penthrox product.

What is Penthrox?

Penthrox, or the green whistle, is a fast onset, non-opioid analgesic. It is indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures.

It has been used safely and effectively for over 40 years in Australia with more than 5 million units sold.

In recent times the company has been looking at expanding its use, hence today's announcement.

What did Medical Developments International announce?

This morning the healthcare company announced that data across 11 abstracts of studies conducted throughout Europe have demonstrated multiple positive results of Penthrox.

This includes Penthrox demonstrating superiority over intravenous (IV) morphine, paracetamol, ketoprofen, and NSAIDS within a trauma setting.

It also found that Penthrox added to the standard of care (SoC) demonstrates superiority over SoC plus a placebo within a trauma setting.

The product was also successful in dislocation injuries. Its use resulted in reduced time spent in the Emergency Departments, which improves the patient experience and reduces crowding.

The release explains that other studies confirmed previously published data. This includes Penthrox being an efficacious, well tolerated/safe and rapidly acting analgesic in trauma settings.

Another positive was that the studies commonly reported that Penthrox exceeded patient/clinician expectations and/or resulted in a high degree of treatment satisfaction from patients and health care professionals.

The company's CEO, John Sharman, was delighted with the study results.

He said: "We are delighted with the results of these recent European clinical trials demonstrating superiority of Penthrox over Standard of Care treatments (intravenous (IV) morphine, IV paracetamol, ketoprofen or NSAIDS) within the acute trauma setting. This reinforces the global potential for Penthrox as a simple, fast and effective non-opioid pain medication."

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Mini house on a laptop.
Dividend Investing

Do ASX 200 dividend shares out-earn Aussie property?

We compare the forecast FY25 dividend yields of the top 10 ASX 200 companies to rental property yields.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Best Shares

Top ASX shares to buy with $500 in November 2024

$500 worth of ASX shares might not sound like a huge investment. But, to realise the benefits of compounding, you…

Read more »

A diverse group of people form a circle at a park and raise their arms together.
Share Market News

Here are the top 10 ASX 200 shares today

ASX investors ended the trading week on a high note this Friday...

Read more »

Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Catapult, De Grey Mining, Domino's, and Nufarm shares are charging higher

These shares are ending the week strongly. But why?

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Three analysts look at tech options on a wall screen
Technology Shares

Up 70%, is it too late to invest in Xero shares?

This ASX tech darling hit a new all-time share price record yesterday.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Healius, Opthea, Peninsula Energy, and Wildcat shares are falling today

These shares are having a tough finish to the week. But why?

Read more »